Accurate characterization of prostate cancers is a major problem facing both for managing individual patients and for the selection and monitoring of subjects in clinical trials. This project, now completed its 13th year, is focused on the development and application of 3D MR spectroscopic imaging to address this clinical problem by providing metabolic assessments of the presence and extent of human prostate cancers. This project has been extremely successful, resulting in the technical development of specialized MR methods, improved understanding of metabolite levels in normal and cancerous prostate tissues, and also in supporting the development of clinical prostate MRSI products that are now widely available on commercial 1.5T scanners. Although 1.5T prostate MRSI is now FDA approved and widely used, there is increasing desire from referring physicians, radiologists, prostate cancer research community, and even patients themselves for 3T prostate MRSI with its potential doubling in performance. The development of 3T prostate MRSI has, however, turned out to be a highly complex task and has required a major redesign of virtually all aspects of the acquisition and analysis techniques developed for 1.5T. In this renewal project, we will develop and apply new 3T MRSI methods with the goal of improving the sensitivity and accuracy for characterizing prostate cancer presence and extent. Our preliminary 3T studies have demonstrated challenges in applying this technique at high field, but also have shown major improvements in SNR and spectral resolution that indicate a great potential for significant improvements in accurately measuring prostate cancer extent before and following therapy. While our preliminary 3T MRSI results have shown dramatic improvements in spatial and spectral resolution for prostate cancer characterization, the prototype methods require further development and the benefit of 3T prostate MRSI is yet to be defined. In this project we will develop new specialized 3T prostate MRSI techniques and apply them in patient studies to determine: a) improvements over 1.5T studies, b) sensitivity, specificity and volume accuracy measurements in prostatectomy patients, and the c) ability to detect and monitor hormone therapy response.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Medical Imaging Study Section (MEDI)
Program Officer
Zhang, Huiming
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Schools of Medicine
San Francisco
United States
Zip Code
Zhang, V Y; Westphalen, A; Delos Santos, L et al. (2014) The role of metabolic imaging in radiation therapy of prostate cancer. NMR Biomed 27:100-11
Westphalen, Antonio C; Reed, Galen D; Vinh, Phillip P et al. (2012) Multiparametric 3T endorectal mri after external beam radiation therapy for prostate cancer. J Magn Reson Imaging 36:430-7
Reed, Galen; Cunha, J Adam; Noworolski, Susan et al. (2011) Interactive, multi-modality image registrations for combined MRI/MRSI-planned HDR prostate brachytherapy. J Contemp Brachytherapy 3:26-31
Keshari, K R; Tsachres, H; Iman, R et al. (2011) Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment. NMR Biomed 24:691-9
Verma, Sadhna; Rajesh, Arumugam; Futterer, Jurgen J et al. (2010) Prostate MRI and 3D MR spectroscopy: how we do it. AJR Am J Roentgenol 194:1414-26
Noworolski, Susan M; Reed, Galen D; Kurhanewicz, John et al. (2010) Post-processing correction of the endorectal coil reception effects in MR spectroscopic imaging of the prostate. J Magn Reson Imaging 32:654-62
Fradet, Vincent; Kurhanewicz, John; Cowan, Janet E et al. (2010) Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology 256:176-83
Osorio, Joseph A; Xu, Duan; Cunningham, Charles H et al. (2009) Design of cosine modulated very selective suppression pulses for MR spectroscopic imaging at 3T. Magn Reson Med 61:533-40
Umbehr, Martin; Bachmann, Lucas M; Held, Ulrike et al. (2009) Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. Eur Urol 55:575-90
Weinreb, Jeffrey C; Blume, Jeffrey D; Coakley, Fergus V et al. (2009) Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 251:122-33

Showing the most recent 10 out of 49 publications